We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Miles
Parkes
miles.parkes@addenbrookes.nhs.uk
Mrs
Rachel
Simpkins
rachel.simpkins@bioresource.nihr.ac.uk
Laetitia
Pele
laetitia.pele@bioresource.nihr.ac.uk
Ms
Sarah
Hearn
sarah.hearn@paediatrics.ox.ac.uk
sarah
hearn
Sarah.Hearn@ouh.nhs.uk
Hazel
Johnson
hazel.johnson@ndm.ox.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Noninfective enteritis and colitis
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Working with the NIHR Bioresource, we are proposing to develop a centralised national recallable bioresource of 25,000 patients with Crohn's disease or ulcerative colitis (collectively inflammatory bowel disease / IBD) to support scientific and clinical IBD research. Key features of IBD Bioresource:1. DNA and serum + clinical and genetic data from 25,000 IBD patients recruited UKwide stored in a central biorepository funded by NIHR Bioresource 2. 1000 newly diagnosed IBD patients. Detailed samples unconfounded by treatment or surgery, plus followup samples + clinical data 3. Recallability run by the NIHR Bioresource office, allowing patients stratified by clinical subtype or carriage of specific IBD genetic risk variants to be recruited for stratified 'stage 2' scientific studies or clinical trials (each stage 2 study would require separate funding and new consent for each subject).IBD affects 4 per 1000 Europeans, peaking in young adults. Despite intensive medical therapies ~50% of patients require major surgery +/colostomy for treatment failure or complications. There is a pressing need to understand the causes of IBD and develop better treatments.Since 2007 we and others have identified >160 distinct genetic risk factors for IBD. The next steps require additional sequencing for rare variants and functional analysis, to understand how associated variants disturb cell function to cause IBD; and translation of this knowledge for clinical benefit. These require access to a large Bioresource of patients of known or ascertainable genotype, to obtain fresh samples for analysis or to recruit patients to stratified clinical trials.'Recallability' is a key novel feature for our disease area. The ethical framework for this has been established by the NIHR Cambridge Bioresource which since 2007 has run a programme of ‘recallability-by-genotype’ for healthy individuals. Our IBD Bioresource will be part of the NIHR Bioresource, and will extend recallable functionality to IBD allowing translation of recent genetic advances.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patients who do not have a confirmed diagnosis of IBD, or who are not able or willing to be notified of and recalled for future 'stage 2'studies
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Hazel
Johnson
hazel.johnson@ndm.ox.ac.uk
Ms
Sarah
Hearn
sarah.hearn@paediatrics.ox.ac.uk
Laetitia
Pele
laetitia.pele@bioresource.nihr.ac.uk
Mrs
Rachel
Simpkins
rachel.simpkins@bioresource.nihr.ac.uk
sarah
hearn
Sarah.Hearn@ouh.nhs.uk
Dr
Miles
Parkes
miles.parkes@addenbrookes.nhs.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by Medical Research Council (MRC); Wellcome Trust; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 20664
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
